EGFR expression in tumour tissue in this trial was determined by immunohistochemistry; however, the optimal biomarker for the selection of patients with NSCLC for treatment with EGFR inhibitors remains to be determined. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.